Stacy Markel Biography and Net Worth

Chief People Officer of Nuvation Bio

Ms. Markel joined Nuvation Bio in 2019. Previously, she served as Executive Vice President, Human Resources, at Rigel Pharmaceuticals, working collaboratively with the CEO and Executive Committee to support the successful evolution of the company from R&D to commercial stage. Prior to that role, Ms. Markel served as Senior Vice President of Human Resources at Portola Pharmaceuticals, Inc., where she helped successfully transition the company from a development-stage company to a commercial-stage company, preparing the organization for the launch of its first marketed product. Prior to Portola, Ms. Markel served as Senior Vice President of Human Resources and Professional Development at Actelion Pharmaceuticals, Ltd., where she was a member of the Executive Leadership Team and Global Human Resources Leadership Team. She was instrumental in the growth of the organization and in positioning culture as a key advantage in attracting and retaining talent. Ms. Markel has over 25 years of business experience in the pharmaceutical/biotechnology industry. She began her career in sales and sales management with Roche Laboratories. Ms. Markel earned a Bachelor’s degree from the University of California, Davis.

What is Stacy Markel's net worth?: The estimated net worth of Stacy Markel is at least $180.72 thousand as of June 23rd, 2026. Ms. Markel owns 32,591 shares of Nuvation Bio stock worth more than $180,717 as of June 29th. This net worth evaluation does not reflect any other assets that Ms. Markel may own. Learn More about Stacy Markel's net worth.
How do I contact Stacy Markel?: The corporate mailing address for Ms. Markel and other Nuvation Bio executives is 1500 BROADWAY SUITE 1401, NEW YORK NY, 10036. Nuvation Bio can also be reached via phone at 332-208-6102 and via email at [email protected]. Learn More on Stacy Markel's contact information.
Has Stacy Markel been buying or selling shares of Nuvation Bio?: Over the course of the past ninety days, Stacy Markel has sold $753,750.00 in Nuvation Bio stock. Most recently, Stacy Markel sold 125,000 shares of the business's stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $6.03, for a transaction totalling $753,750.00. Following the completion of the sale, the insider now directly owns 32,591 shares of the company's stock, valued at $196,523.73. Learn More on Stacy Markel's trading history.
Who are Nuvation Bio's active insiders?: Nuvation Bio's insider roster includes Kim Blickenstaff (Director), Xiangmin Cui (Director), Jennifer Fox (CFO & Sec. ), Gary Hattersley (Chief Scientific Officer), David Hung (Founder), David Hung (CEO), Stacy Markel (Chief People Officer), Robert Mashal (Director), Oleg Nodelman (Director), Philippe Sauvage (CFO), and Kerry Wentworth (Chief Regulatory Officer). Learn More on Nuvation Bio's active insiders.
Are insiders buying or selling shares of Nuvation Bio?: During the last year, Nuvation Bio insiders bought shares 1 times. They purchased a total of 25,000 shares worth more than $118,250.00. During the last year, insiders at the sold shares 13 times. They sold a total of 842,418 shares worth more than $4,809,412.18. The most recent insider tranaction occured on June, 23rd when insider Stacy Markel sold 125,000 shares worth more than $753,750.00. Insiders at Nuvation Bio own 30.1% of the company. Learn More about insider trades at Nuvation Bio.
Information on this page was last updated on 6/23/2026.

Stacy Markel Insider Trading History at Nuvation Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/23/2026	Sell	125,000	$6.03	$753,750.00	32,591

Stacy Markel Buying and Selling Activity at Nuvation Bio

Nuvation Bio Company Overview

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Today's Range

Now: $5.60

$5.39

$5.65

50 Day Range

MA: $4.94

$4.22

$6.52

2 Week Range

Now: $5.60

$1.87

$9.75

Volume

8,522,798 shs

Average Volume

5,294,578 shs

Market Capitalization

$1.95 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.52